These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35413886)

  • 21. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
    Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
    J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
    Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
    Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
    Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial.
    Lertwattanachai T; Montakantikul P; Tangsujaritvijit V; Sanguanwit P; Sueajai J; Auparakkitanon S; Dilokpattanamongkol P
    J Intensive Care; 2020; 8():26. PubMed ID: 32318268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of CRRT with oXiris filter on hemodynamic instability in surgical septic shock with AKI: A pilot randomized controlled trial.
    Feng J; Zhang S; Ai T; Wang L; Gao Y; Li W; Zhu M
    Int J Artif Organs; 2022 Oct; 45(10):801-808. PubMed ID: 35864718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Target Attainment of 3-Hour Extended Infusion of Meropenem in Patients With Septic Burns.
    Messiano CG; Morales Junior R; Pereira GO; Silva Junior EMD; Gomez DS; Santos SRCJ
    Clin Ther; 2022 Apr; 44(4):624-629. PubMed ID: 35260257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial.
    David S; Bode C; Stahl K;
    Trials; 2023 Apr; 24(1):277. PubMed ID: 37061693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The timing of continuous renal replacement therapy initiation in sepsis-associated acute kidney injury in the intensive care unit: the CRTSAKI Study (Continuous RRT Timing in Sepsis-associated AKI in ICU): study protocol for a multicentre, randomised controlled trial.
    Chen WY; Cai LH; Zhang ZH; Tao LL; Wen YC; Li ZB; Li L; Ling Y; Li JW; Xing R; Liu XY; Lin ZD; Deng ZT; Wang SH; Lin QH; Zhou DR; He ZJ; Xiong XM
    BMJ Open; 2021 Feb; 11(2):e040718. PubMed ID: 33608398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease.
    Hassanpour R; Ziaie S; Kobarfard F; Kouchek M; Miri M; Ahmadi Koomleh A; Shojaei S; Salarian S; Pourheidar E; Nezarat F; Sistanizad M
    Eur J Clin Pharmacol; 2021 Jun; 77(6):831-840. PubMed ID: 33409684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
    Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
    Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual Meropenem Clearance in Infants on ECMO and CVVHDF is Difficult to Predict: A Case Report and Review of the Literature.
    Jabareen A; Nassar L; Karasik M; Efrati E; Hadash A; Kassis I; Kurnik D
    Pediatr Infect Dis J; 2022 Feb; 41(2):117-120. PubMed ID: 34966143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.
    Villa G; Di Maggio P; De Gaudio AR; Novelli A; Antoniotti R; Fiaccadori E; Adembri C
    Crit Care; 2016 Nov; 20(1):374. PubMed ID: 27863531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).
    Zimmermann JB; Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S
    Trials; 2017 Nov; 18(1):530. PubMed ID: 29126416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial.
    Nowak-Kózka I; Polok KJ; Górka J; Fronczek J; Gielicz A; Seczyńska B; Czuczwar M; Kudliński B; Szczeklik W
    Pharmacol Rep; 2020 Feb; 72(1):147-155. PubMed ID: 32016840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.